MINDCURE was formed as a response to a world suffering and in urgent need of effective treatments in the midst of a mental health crisis. MINDCURE is exploring related and diverse therapeutic areas beyond psychiatry, which include therapeutics for neuropathic pain, neurodegenerative disease, and mental health.
MINDCURE is pursuing technology and products that are complimentary or related to its mission to identify, develop, and commercialize products that enhance mental health and wellness, ease suffering, and increase productivity.
MINDCURE seeks to commercialize the therapeutic potential of nootropics, psychoactive products, and psychedelic substances that promote productivity and enhance mental health.
MINDCURE is evaluating potential research programs, protocols, and supportive infrastructure to drive clinical research.
MINDCURE is evaluating the legal and commercial viability of the use of psychedelic compounds such as psilocybin as part of its future product candidates.
This sphere calls for Mind Cure to evaluate a path to the manufacture, import and supply of traditional and novel candidate active pharmaceutical agents for North American supply.
Taken together, MINDCURE’s Five Spheres™, including research, discovery, clinical programs, technology, and GMP scale-up, will guide us in the adoption of psychedelic-assisted psychotherapy, regenerative medicine, and neuroscience. Beyond the physical and mental benefits, MINDCURE is determined to transform the ideas of today into the products of tomorrow that unify the mind and body in a world suffering from a mental health crisis.
MINDCURE is investigating technology that focuses on the connection between clinical patient‐trials that monitor, collect, or use patient information in order to assist in diagnosis and treatments.
Currently, most patients being treated for mental health concerns do not receive any meaningful data before and after therapy sessions. MINDCURE is investigating technology that could enable the collection of data between sessions. This would equip clinicians with additional patient feedback and data-driven insights into the efficacy of treatments.
The first line of products that MINDCURE has launched are three types of organic mushroom nootropics. These products are distributed under the following product names: MINDCURE Lion’s Mane Focus, MINDCURE Reishi Energy, and MINDCURE Turkey Tail Immunity. Each of these products are available in powdered and capsule form. Visit our product site for more info!
MINDCURE is investing in research programs, protocols, and support infrastructure for conducting clinical research. MINDCURE will examine the potential of mental health clinical trial protocols that may include psychoactive and psychedelic based substances, and investigate the ability to conduct clinical trials with Health Canada.
MINDCURE’s product discovery sphere will investigate the potential of new discoveries and explore the therapeutic pathology and regenerative benefits of novel and traditional psychoactive chemical compounds in clinical studies. This investigation may include new and improved psychedelic-inspired product candidates ranging from proprietary new-psychedelic compounds to non‐psychedelics with medicinal properties.
The process will comply with regulatory certifications and licensing within Canadian federal regulatory agencies (including Health Canada) and the US Federal regulatory agencies (including the FDA).
The importation of traditional and novel psychoactive substances into North America could be used to service clinical research programs and satisfy underserviced access to psychoactive pharmaceutical ingredients (API) for research.